Study documents opioid abuse following urologic surgery

May 30, 2017

MAYWOOD, IL - About 1 in 1,111 patients who undergo urologic surgery for conditions such as prostate cancer and kidney stones experience opioid dependence or overdose (ODO), a Loyola Medicine study has found.

Patients at highest risk for ODO were younger, underwent inpatient surgery, had longer hospital stays, were on Medicaid or Medicare or had a history of depression or chronic obstructive pulmonary disease.

The study by co-first authors Arpeet Shah, MD, and Robert Blackwell, MD, and senior author Gopal Gupta, MD, is published in the Journal of Urology.

The opioid epidemic is a growing problem in the United States. Every day, more than 90 Americans die after overdosing on opioids, and the economic burden of prescription opioid misuse in the United States totals $78.5 billion per year, according to the National Institute on Drug Abuse. In 2012, 259 million prescriptions were written for opioids - enough to supply every American adult with a prescription.

"With the rates of opioid dependence and overdose skyrocketing and physician prescriptions representing the center of the supply chain, it is imperative for surgeons to balance the pain-control needs of patients with the devastating consequences of America's epidemic," researchers wrote.

Opioids are a class of drugs that include illegal drugs such as heroin and legal pain relievers including Oxycontin, Vicodin, codeine and morphine.

"It is a surgeon's ethical duty and legal responsibility to help minimize patient discomfort after surgery," Loyola researchers wrote. "However, the ubiquitous use of opioids has led to a growing epidemic of addiction, dependence and overdose."

Researchers reviewed the records of 675,527 patients who underwent inpatient and outpatient urologic surgery between 2007 and 2011. Researchers used powerful computers to mine data from the Healthcare Cost and Utilization Project Inpatient, Ambulatory Surgery and Emergency Department data sets. Patients who had been diagnosed with ODO prior to surgery were excluded from the study.

Urologic surgeries include kidney stone removals, hernia repairs and surgeries involving the prostate, kidney and bladder. Overall, 0.09 percent of patients were diagnosed with ODO within a year of surgery. This is consistent with findings from previous studies.

"While rare, this potentially devastating complication is likely under-reported, as many of those with an opioid dependence are not diagnosed until they seek treatment or have a complication from the dependence such as overdose," researchers wrote.

The highest rates of ODO occurred among patients who underwent kidney stone procedures (0.15 percent) or major kidney surgery (0.12 percent).

Physicians can reduce ODO by implementing such measures as screening for ODO risk factors when scheduling surgery and using the shortest duration and lowest effective doses possible. No patient should be prescribed opioids for more than two weeks, and patients should be re-evaluated to determine whether refills are necessary.
The study is titled "Rates and risk factors for opioid dependence and overdose after urologic surgery."

The study was conducted by Loyola's predictive analytics program, One:MAP Division of Clinical Informatics and Analytics. The program conducts health outcomes studies involving large new databases, electronic medical records and powerful computers. The program is directed by Paul Kuo, MD, chair of Loyola's department of surgery and a co-author of the opioid study.

Loyola University Health System

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to